FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136060315> ?p ?o ?g. }

• W3136060315 endingPage "619.e8" @default.
• W3136060315 startingPage "619.e1" @default.
• W3136060315 abstract "The optimal prophylaxis regimen for graft-versus-host disease (GVHD) in the setting of single-locus mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation (alloHSCT) is unclear. The use of high-dose post-transplant cyclophosphamide (PTCy) after haploidentical transplantation is effective at overcoming the negative impact of HLA disparity on survival. Limited information is available regarding the efficacy of this strategy in alloHSCT from MMUDs. Most of the published studies have used the triple immunosuppressant model of haploidentical transplant combining PTCy with calcineurin inhibitors and mycophenolate mofetil or methotrexate. In our study, we propose the use of a simpler GVHD prophylaxis protocol comprising PTCy in combination with tacrolimus for MMUD and matched unrelated donor (MUD) alloHSCT. We performed a retrospective analysis of 109 consecutive recipients of alloHSCT from unrelated donors (MMUD, n = 55; MUD, n = 54) in a single center. Graft source was primarily peripheral blood (98%). No differences were observed between the MMUD and MUD groups with respect to 100-day cumulative incidence of grade II to IV acute GVHD (aGVHD; 31% versus 32%, respectively, P = .9), grade III to IV aGVHD (9% versus 7%, P = .7), and moderate/severe chronic GVHD (cGVHD) at 2 years (18% versus 14%, P = .6). Both groups showed similar cumulative incidence of 1 year nonrelapse mortality (13% versus 9%; P = .5) and 3-year relapse rates (24% versus 25%, P = .7). Progression-free survival and overall survival at 3 years for MMUD and MUD were 56% and 57% (P = .9) and 64% and 65% (P = .6), respectively. The 3-year probability of survival free of moderate/severe cGVHD and relapse was 56% and 55%, respectively. GVHD prophylaxis with PTCy and tacrolimus achieves low rates of severe aGVHD and cGVHD, as well as good survival outcomes, in recipients of both MMUD and MUD peripheral blood alloHSCT. This strategy overcomes the negative impact of single-locus HLA disparity." @default.
• W3136060315 created "2021-03-29" @default.
• W3136060315 creator A5000087123 @default.
• W3136060315 creator A5001665469 @default.
• W3136060315 creator A5008597414 @default.
• W3136060315 creator A5012535366 @default.
• W3136060315 creator A5015898454 @default.
• W3136060315 creator A5024363311 @default.
• W3136060315 creator A5032058266 @default.
• W3136060315 creator A5055762764 @default.
• W3136060315 creator A5076935487 @default.
• W3136060315 creator A5077389546 @default.
• W3136060315 creator A5087916331 @default.
• W3136060315 creator A5088657371 @default.
• W3136060315 date "2021-07-01" @default.
• W3136060315 modified "2023-10-18" @default.
• W3136060315 title "High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation" @default.
• W3136060315 cites W1856122919 @default.
• W3136060315 cites W1982972606 @default.
• W3136060315 cites W1994780830 @default.
• W3136060315 cites W1998771934 @default.
• W3136060315 cites W2031845161 @default.
• W3136060315 cites W2039334806 @default.
• W3136060315 cites W2055553511 @default.
• W3136060315 cites W2061069485 @default.
• W3136060315 cites W2064085613 @default.
• W3136060315 cites W2068414487 @default.
• W3136060315 cites W2133072316 @default.
• W3136060315 cites W2150999336 @default.
• W3136060315 cites W2290639160 @default.
• W3136060315 cites W2295632274 @default.
• W3136060315 cites W2337759633 @default.
• W3136060315 cites W2481464774 @default.
• W3136060315 cites W2566555955 @default.
• W3136060315 cites W2570187106 @default.
• W3136060315 cites W2618073389 @default.
• W3136060315 cites W2786706578 @default.
• W3136060315 cites W2800808649 @default.
• W3136060315 cites W2922962548 @default.
• W3136060315 cites W2955362686 @default.
• W3136060315 cites W3024604530 @default.
• W3136060315 doi "https://doi.org/10.1016/j.jtct.2021.03.022" @default.
• W3136060315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33895157" @default.
• W3136060315 hasPublicationYear "2021" @default.
• W3136060315 type Work @default.
• W3136060315 sameAs 3136060315 @default.
• W3136060315 citedByCount "12" @default.
• W3136060315 countsByYear W31360603152021 @default.
• W3136060315 countsByYear W31360603152022 @default.
• W3136060315 countsByYear W31360603152023 @default.
• W3136060315 crossrefType "journal-article" @default.
• W3136060315 hasAuthorship W3136060315A5000087123 @default.
• W3136060315 hasAuthorship W3136060315A5001665469 @default.
• W3136060315 hasAuthorship W3136060315A5008597414 @default.
• W3136060315 hasAuthorship W3136060315A5012535366 @default.
• W3136060315 hasAuthorship W3136060315A5015898454 @default.
• W3136060315 hasAuthorship W3136060315A5024363311 @default.
• W3136060315 hasAuthorship W3136060315A5032058266 @default.
• W3136060315 hasAuthorship W3136060315A5055762764 @default.
• W3136060315 hasAuthorship W3136060315A5076935487 @default.
• W3136060315 hasAuthorship W3136060315A5077389546 @default.
• W3136060315 hasAuthorship W3136060315A5087916331 @default.
• W3136060315 hasAuthorship W3136060315A5088657371 @default.
• W3136060315 hasBestOaLocation W31360603151 @default.
• W3136060315 hasConcept C120665830 @default.
• W3136060315 hasConcept C121332964 @default.
• W3136060315 hasConcept C126322002 @default.
• W3136060315 hasConcept C128057223 @default.
• W3136060315 hasConcept C203014093 @default.
• W3136060315 hasConcept C2776694085 @default.
• W3136060315 hasConcept C2776755627 @default.
• W3136060315 hasConcept C2777408962 @default.
• W3136060315 hasConcept C2779972918 @default.
• W3136060315 hasConcept C2780073493 @default.
• W3136060315 hasConcept C2780611847 @default.
• W3136060315 hasConcept C2781059491 @default.
• W3136060315 hasConcept C2909675724 @default.
• W3136060315 hasConcept C2909935303 @default.
• W3136060315 hasConcept C2911091166 @default.
• W3136060315 hasConcept C61511704 @default.
• W3136060315 hasConcept C71924100 @default.
• W3136060315 hasConcept C88879693 @default.
• W3136060315 hasConcept C90924648 @default.
• W3136060315 hasConceptScore W3136060315C120665830 @default.
• W3136060315 hasConceptScore W3136060315C121332964 @default.
• W3136060315 hasConceptScore W3136060315C126322002 @default.
• W3136060315 hasConceptScore W3136060315C128057223 @default.
• W3136060315 hasConceptScore W3136060315C203014093 @default.
• W3136060315 hasConceptScore W3136060315C2776694085 @default.
• W3136060315 hasConceptScore W3136060315C2776755627 @default.
• W3136060315 hasConceptScore W3136060315C2777408962 @default.
• W3136060315 hasConceptScore W3136060315C2779972918 @default.
• W3136060315 hasConceptScore W3136060315C2780073493 @default.
• W3136060315 hasConceptScore W3136060315C2780611847 @default.
• W3136060315 hasConceptScore W3136060315C2781059491 @default.
• W3136060315 hasConceptScore W3136060315C2909675724 @default.
• W3136060315 hasConceptScore W3136060315C2909935303 @default.
• W3136060315 hasConceptScore W3136060315C2911091166 @default.

• next